How many large pharmaceutical companies’ profit revenues can’t even reach the “good value”

WenLao Xue

"Don't always think that the company is big, don't you know if it can reach the cool level?"

The news that Zheng Shuang earned 160 million yuan in 77 days has been one after another in the past two days, and some netizens used this to calculate a year's income-640 million yuan, commonly known as "1 Shuang" unit.

Money is not easy to make, and every document issued by the state revolves around the argument of "to live a tight life".

Yes, the predecessors have had a relaxed life, and it is they who have overdrawn the good luck of the medical industry.

On March 25, the Financial Secretary of the Health Commission announced the departmental budget for 2021.

Let's think about it, when you don't have a lot of money, what will you buy first?

It shouldn't be about buying high-priced ties and sky-high underwear first, but spending the money on the edge.

Companies have money, especially don’t blindly invest.

In addition, from the perspective of circulation supervision, the current legal system construction is quite effective, and the phenomenon of who is weak and who is reasonable is decreasing.

Don't underestimate this case.

With such a comparison, is it clearer to realize the meaning of the current judgment?

It is necessary to ensure the legitimate rights and interests of pharmaceutical companies under normal circumstances, rather than distribution according to noise.

Moreover, due to factors such as medical insurance control fees, pharmaceutical companies must broaden their sales platforms, such as DTP pharmacies.

Many pharmaceutical companies may not have the opportunity to achieve profits of over 100 million yuan, but they have strong capabilities and standards in protecting people's livelihood and health.